Clinical trials: Migraine, Acute
Migraine, Acute Treatment of Migraine
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain")…
- Trial name
- NCT01430442
- Testing
- Rimegepant, Sumatriptan
- Where
- 41 sites in United States
- Volunteers
- 1,026 people
- Sponsor
- Pfizer
Migraine Disorders
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS in patients with a single acute migraine attack with or without aura
- Trial name
- NCT02198339
- Testing
- BIBN 4096 BS
- Volunteers
- 126 people
- Sponsor
- Boehringer Ingelheim
Migraine Headache
Zomig - Treatment of Acute Migraine Headache in Adolescents
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better.
- Trial name
- TEENZ (NCT01211145)
- Testing
- Zolmitriptan
- Where
- 74 sites in United States, Estonia and 6 more
- Volunteers
- 1,653 people
- Sponsor
- AstraZeneca
Migraine
Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)
The purpose of this study is to investigate the safety and tolerability of telcagepant (MK-0974) in the long-term treatment of acute migraine in adult participants.
- Trial name
- NCT00443209
- Testing
- Telcagepant 300 mg soft gel capsules, Telcagepant 280 mg tablets, Rizatriptan 10 mg tablets
- Volunteers
- 1,068 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Migraine
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
This study is intended to evaluate the efficacy and safety of Nerivio, an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine, for the acute treatment of migraine in people with…
- Trial name
- NCT04161807
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Theranica
Acute Migraine
Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
- Trial name
- Zotrip (NCT02745392)
- Testing
- ZP-Zolmitriptan
- Where
- 36 sites in United States
- Volunteers
- 365 people
- Sponsor
- Zosano Pharma Corporation
Migraine Disorders
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.
- Trial name
- NCT00963937
- Testing
- Sumatriptan 25 mg, Sumatriptan 50 mg
- Where
- 16 sites in Japan
- Volunteers
- 178 people
- Sponsor
- GlaxoSmithKline
Migraine, With or Without Aura
Trial in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
- Trial name
- NCT03461757
- Testing
- Rimegepant
- Where
- 69 sites in United States
- Volunteers
- 1,811 people
- Sponsor
- Pfizer
Migraine Headache
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
The study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN Device can reduce the pain and symptoms associated with migraine headaches.
- Trial name
- NCT01462812
- Testing
- Sumatriptan
- Where
- 15 sites in United States
- Volunteers
- 223 people
- Sponsor
- Optinose US Inc.
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine
A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
The purpose of this study is: 1. To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in acute treatment of up to one migraine attract 2. To assess recurrence rate between two group 3.
- Trial name
- NCT00821483
- Testing
- Frovatriptan
- Volunteers
- 298 people
- Sponsor
- SK Chemicals Co., Ltd.
Migraine Headaches
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches
to demonstrate the superiority of Trexima (combination of sumatriptan as the succinate 85 mg and naproxen sodium 500 mg) versus placebo in the acute treatment of migraine to demonstrate the superiority of Trexima versus the…
- Trial name
- NCT00434083
- Testing
- sumatriptan, naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- POZEN
Migraine With and Without Aura
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
This proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen combination to sumatriptan in the acute treatment of migraine.
- Trial name
- NCT03185143
- Testing
- Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine With or Without Aura
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SPARTAN (NCT02605174)
- Testing
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 95 sites in United States
- Volunteers
- 3,005 people
- Sponsor
- Eli Lilly and Company
Migraine
Acute Treatment Trial in Adult Subjects With Migraines
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
- Trial name
- NCT03872453
- Testing
- Zavegepant, Intranasal Aptar Pharma Unit Dose System
- Where
- 82 sites in United States
- Volunteers
- 2,154 people
- Sponsor
- Pfizer
Migraine Disorders
A Study of Gastric Delay in Migraine Patients (3207-003)
A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.
- Trial name
- NCT00548353
- Testing
- MK3207
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine, Acute
Use Of SB-705498 In The Acute Treatment Of Migraine
Despite the success of the triptan class of drugs, approximately 60% of patients who take medication at the moderate to severe pain stage of acute migraine, still have pain of mild or greater degree at 2 hrs post dose.
- Trial name
- NCT00269022
- Testing
- SB-705498
- Where
- 4 sites in Australia, Canada and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Migraine
Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition
The purpose of this study is to evaluate the pharmacokinetics (PK) of BMS-927711 during migraine and non-migraine condition.
- Trial name
- NCT01445067
- Testing
- BMS-927711 (CGRP Antagonist)
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer
Migraine
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101.
- Trial name
- NCT06728553
- Testing
- MTX101
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Manistee Therapeutics
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine…
- Trial name
- NP101-009 (NCT00806546)
- Testing
- NP101
- Where
- 31 sites in United States
- Volunteers
- 514 people
- Sponsor
- NuPathe Inc.